New scan could spare men unnecessary biopsies

NCT ID NCT07258056

Recruiting now Diagnosis Sponsor: Mads Ryo Jochumsen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special PET/MRI scan (PSMA) can find aggressive prostate cancer better than standard biopsies in men with a negative MRI but still suspected of having cancer. One hundred men will receive both the new targeted biopsies and standard systematic biopsies. The goal is to see if the new method can safely avoid biopsies when the scan is negative, while catching more aggressive cancers when positive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PSMA PET/MRI imaging and targeted biopsies
What this could lead to: If successful, this could reduce unnecessary biopsies and improve detection of aggressive prostate cancer in men with negative MRI scans.
What could go wrong: This is an early-stage diagnostic study with only 100 participants. The new method may not prove more accurate than standard biopsies, and results may not apply to all men.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Aarhus University Hospital
RECRUITING

Aarhus N, Aarhus, 8200, Denmark
Goedstrup Hospital
RECRUITING

Herning, Herning, 7400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.